コーパス検索結果 (1語後でソート)
  通し番号をクリックするとPubMedの該当ページを表示します
  
   1 vanced and relapsed peritoneal metastasis in epithelial ovarian carcinoma.                           
     2 tients with platinum-resistant or refractory epithelial ovarian carcinoma.                           
     3 l cells is present in the normal ovaries and epithelial ovarian carcinoma.                           
     4 ells derived from nine normal ovaries and 21 epithelial ovarian carcinoma.                           
     5 ological entity compared with grade 1 serous epithelial ovarian carcinoma.                           
     6  criterion being a pathological diagnosis of epithelial ovarian carcinoma.                           
     7  primary breast carcinomas and in 55 primary epithelial ovarian carcinomas.                          
     8 ve serum TF levels in 98 women with invasive epithelial ovarian carcinoma, 30 with low malignant pote
     9  this study, we show that in human and mouse epithelial ovarian carcinoma and mouse lung carcinoma, t
    10  allelic loss on chromosome 7q31 in invasive epithelial ovarian carcinomas and borderline ovarian tum
  
    12 acizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous 
    13 rm survival rates for patients with advanced epithelial ovarian carcinoma (EOC) remain disappointing,
  
    15 ly identified in gene expression profiles of epithelial ovarian carcinomas (EOC) is the gene for huma
    16  clinical outcome of high-grade serous (HGS) epithelial ovarian carcinomas (EOC), we evaluated the as
    17 e glycosyltransferase GnT-III is elevated in epithelial ovarian carcinomas (EOCs) and leads to the pr
    18 f targeted therapy to date in the setting of epithelial ovarian carcinoma has come from angiogenesis 
    19 es (P-A and P-C) in the destruction of human epithelial ovarian carcinoma heterotransplanted in the n
  
    21 hromosomes 5 and 6 in 29 primary early-stage epithelial ovarian carcinomas including 3 microscopicall
  
  
  
    25 profiled microRNA (miR) expression in serous epithelial ovarian carcinomas to assess the possibility 
    26 sessment of clinical outcomes with regard to epithelial ovarian carcinoma tumor methylation to date. 
  
    28 ion (32P) therapy in patients with stage III epithelial ovarian carcinoma who have no detectable evid
    29 n has modest activity in women with advanced epithelial ovarian carcinoma who have progressed or not 
    30  a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or t
    31  analysis was performed on 300 patients with epithelial ovarian carcinoma with at least one measureme
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。